Risk of amputation with canagliflozin across categories of age and cardiovascular risk in three US nationwide databases: cohort study.

ABSTRACT:

Objective

To estimate the rate of lower limb amputation among adults newly prescribed canagliflozin according to age and cardiovascular disease.

Design

Population based, new user, cohort study.

Data sources

Two commercial and Medicare claims databases, 2013-17.

Participants

Patients newly prescribed canagliflozin were propensity score matched 1:1 with patients newly prescribed a glucagon-like peptide-1 (GLP-1) receptor agonist. Hazard ratios and rate differences per 1000 person years were computed for the rate of lower limb amputation in the following four groups: group 1, patients aged less than 65 years without baseline cardiovascular disease; group 2, patients aged less than 65 with baseline cardiovascular disease; group 3, patients aged 65 or older without

SUBMITTER: Fralick M 

PROVIDER: S-EPMC7445737 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature